DRUGS & SUPPLEMENTS
What is the dose of the medication you are taking?
Gine Zalain® (sertaconazole nitrate) cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum [see Clinical Studies (14) ].
Gine Zalain cream 2% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. (1)
In the treatment of interdigital tinea pedis, Gine Zalain cream, 2%, should be applied twice daily for 4 weeks. Sufficient amount of Gine Zalain cream, 2%, should be applied to cover both the affected areas between the toes and the immediately surrounding healthy skin of patients with interdigital tinea pedis.
Not for ophthalmic, oral, or intravaginal use.
Gine Zalain cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks. (2)
Not for ophthalmic, oral, or intravaginal use. (2)
Cream, 2%. Each gram of Gine Zalain cream, 2%, contains 17.5 mg of sertaconazole (as Gine Zalain, 20 mg) in a white cream base.
Cream, 2%. (3)
If irritation develops, treatment should be discontinued and appropriate therapy instituted.
Physicians should exercise caution when prescribing Gine Zalain cream, 2%, to patients known to be sensitive to azole antifungals, since cross-reactivity may occur.
Most common adverse reactions observed in clinical trials were contact dermatitis, dry skin, burning skin, application site skin tenderness. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.
In clinical trials, cutaneous adverse events occurred in 7 of 297 (2%) subjects (2 of them severe) receiving Gine Zalain® cream, 2%, and in 7 of 291 (2%) subjects (2 of them severe) receiving vehicle. These reported cutaneous adverse events included contact dermatitis, dry skin, burning skin, application site skin tenderness.
In a dermal sensitization trial, 8 of 202 evaluable subjects tested with Gine Zalain® cream, 2%, and 4 of 202 evaluable subjects tested with vehicle, exhibited a slight erythematous reaction in the challenge phase. There was no evidence of cumulative irritation or contact sensitization in a repeated insult patch test involving 202 healthy volunteers.
The following adverse reactions have been identified during post-approval use of Gine Zalain cream, 2%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In post-marketing surveillance for Gine Zalain cream, 2%, the following were reported:
Cutaneous adverse events: erythema, pruritus, vesiculation, desquamation, and hyperpigmentation.
Pregnancy Category C.
There are no adequate and well-controlled studies conducted with Gine Zalain cream in pregnant women. Gine Zalain cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Reproduction studies have not been performed with Gine Zalain cream. Gine Zalain did not produce any evidence of maternal toxicity, embryotoxicity or teratogenicity in rats and rabbits at an oral dose of 160 mg/kg/day and 80 times (rabbits) the maximum recommended human dose based on a body surface area comparison). A reduction in live birth indices and an increase in the number of still-born pups were seen at doses of 80 and 160 mg/kg/day Gine Zalain in an oral peri- and post-natal development study in rats.
It is not known if sertaconazole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when prescribing Gine Zalain cream, 2%, to a nursing woman.
The efficacy and safety of Gine Zalain cream, 2%, have not been established in pediatric patients below the age of 12 years.
Clinical trials of Gine Zalain cream, 2%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Gine Zalain (sertaconazole nitrate) cream, 2%, is for topical application. It contains the azole antifungal, Gine Zalain. Gine Zalain contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.
Gine Zalain is designated chemically as (±)-1-[2,4-dichloro-β-[(7-chlorobenzo-[b]thien-3-yl)methoxy]phenethyl]imidazole nitrate. It has a molecular weight of 500.8. The molecular formula is C20H15Cl3N2OS ∙ HNO3, and the structural formula is as follows:
Gine Zalain is a white or almost white powder. It is practically insoluble in water, soluble in methanol, sparingly soluble in alcohol and in methylene chloride. Each gram of Gine Zalain cream, 2%, contains 17.5 mg of sertaconazole (as Gine Zalain, 20 mg) in a white cream base of ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, sorbic acid and purified water.
Gine Zalain cream is an azole antifungal [see Clinical Pharmacology ].
In a multiple dose pharmacokinetic trial that included 5 male subjects with interdigital tinea pedis (range of diseased area, 42 - 140 cm2; mean, 93 cm2), Gine Zalain cream, 2%, was topically applied every 12 hours for a total of 13 doses to the diseased skin (0.5 grams Gine Zalain per 100 cm2). Sertaconazole concentrations in plasma measured by serial blood sampling for 72 hours after the thirteenth dose were below the limit of quantitation (2.5 ng/mL) of the analytical method used.
Mechanism of Action :
Sertaconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. Ergosterol is a key component of fungal cell membranes and lack of this component leads to fungal cell injury by leakage of key constituents in the cytoplasm from the cell.
Activity In Vitro and in Clinical Infections :
Gine Zalain has been shown to be active against isolates of the following microorganisms in clinical infections [see Indications and Usage (1) ].
In a rat dermal carcinogenicity study, topical administration of Gine Zalain cream for up to 102 weeks did not increase the number of neoplastic lesions compared to control animals, at Gine Zalain doses of up to 800 mg/kg/day (approximately 200 times the maximum recommended human dose based on a body surface area comparison).
No clastogenic potential was observed in a mouse micronucleus test. Gine Zalain was considered nonclastogenic in the in vivo mouse sister chromatid exchange assay. There was no evidence that Gine Zalain induced unscheduled DNA synthesis in primary rat hepatocyte cultures.
At oral doses up to 60 mg/kg/day (16 times the maximum recommended human dose based on a body surface area comparison), Gine Zalain exhibited no toxicity or adverse effects on reproductive performance or fertility in male or female rats.
In two randomized, double-blind, clinical trials, subjects 12 years and older with interdigital tinea pedis applied either Gine Zalain cream, 2%, or vehicle, twice daily for four weeks. Subjects with moccasin-type (plantar) tinea pedis and/or onychomycosis were excluded from the trial. Two weeks after completion of therapy (six weeks after beginning therapy), subjects were evaluated for signs and symptoms related to interdigital tinea pedis.
Treatment outcomes are summarized in the table below.
|Trial 1||Trial 2|
In clinical trials, complete cure in sertaconazole treated subjects was achieved in 32 of 160 (20%) subjects with Trichophyton rubrum, in 7 of 28 (25%) subjects with Trichophyton mentagrophytes and in 1 of 13 (15%) subjects with Epidermophyton floccosum.
Gine Zalain cream, 2%, is white in color and supplied in tubes in the following size:
Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°-30°C (59°-86°F).
See FDA-approved Patient Labeling (Patient Information)
The patient should be instructed to:
Gine Zalain (er-tack-zo)
(sertaconazole nitrate) cream, 2%
Important information: Gine Zalain cream is for use on skin only. Do not use Gine Zalain cream in your eyes, mouth, or vagina.
What is Gine Zalain cream?
Gine Zalain cream is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older with normal immune systems.
It is not known if Gine Zalain cream is safe and effective in children under 12 years of age.
What should I tell my healthcare provider before using Gine Zalain cream?
Before using Gine Zalain cream, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use Gine Zalain cream?
What are the possible side effects of Gine Zalain cream?
The most common side effects of Gine Zalain cream include: redness, itching, dry skin, burning, blistering, swelling, drainage and skin tenderness at the treated skin areas. Tell your healthcare provider if you have any of these skin reactions.
These are not all the possible side effects of Gine Zalain cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Gine Zalain cream?
General information about the safe and effective use of Gine Zalain cream
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about Gine Zalain cream that is written for health professionals. Do not use Gine Zalain cream for a condition for which it was not prescribed. Do not give Gine Zalain cream to other people, even if they have the same symptoms you have. It may harm them.
What are the ingredients in Gine Zalain cream?
Active ingredient: Gine Zalain
Inactive ingredients: ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, sorbic acid and purified water
Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807
Manufactured by: DPT Laboratories, Ltd., San Antonio, TX 78215
Product of Spain
For more information call 1-800-321-4567.
This Patient Information has been approved by the U.S. Food and Drug Administration.
PRINCIPAL DISPLAY PANEL - 60 g Tube
(sertaconazole nitrate) cream, 2%
For Topical Use Only – Not for Oral, Ophthalmic, or Intravaginal Use
PRINCIPAL DISPLAY PANEL - 60 g Tube
Depending on the reaction of the Gine Zalain after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Gine Zalain not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Gine Zalain addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology